Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome.

During the course of treatment, there was a significant decrease in the level of IgM and only a decreasing trend in IgG levels ( Figure 5 ).

also in 47,180 other papers

While an increasing trend towards to HCs was observed in responders at the end of month 12, non-responders continued to have low alpha diversity at this time point.

also in 63,971 other papers